News

Jan 10, 2024

Biopharmaceutical Excipient Manufacturing Market Grow at a CAGR of 9.7% from 2023 to 2031

Companies covered in this report are ABITEC (US), Avantor (US), BASF Pharma

Companies covered in this report are ABITEC (US), Avantor (US), BASF Pharma (Germany), Corden Pharma (Germany), DFE Pharma (Germany), Evonik (Germany), Kirsch Pharma (Germany), Merck KGaA (Germany

Jersey City, NJ, May 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the Global Biopharmaceutical Excipient Manufacturing Market- by Product Type ( Solubilizers & Surfactants/Emulsifiers (Triglycerides, Esters, Others (Sodium Cocoyl Glutamate, Glyceryl Caprylate; Citric Acid; Polyglyceryl-6 Oleate; Sodium Surfactin)), Polyols (Mannitol, Sorbitol, Others (Lactitol, Isomalt, xylitol)), Carbohydrates (Sucrose, Dextrose, Starch, Others (Lactose, Cellolose, Fructose)) and Others), Type of Biologics (Antibodies, Vaccines, Cell Therapies and Specialty Excipients), Scale of Operation (Commercial, Research), Type of Biologics (Antibodies, Vaccines, Cell Therapies, and Other Biologics) Trends, Industry Competition Analysis, Revenue and Forecast To 2031.

"According to the latest published InsightAce Report, the global Biopharmaceutical Excipient Manufacturing market was valued at US$ 1,259.8 Million in 2021 & expected to reach US$ 2,624.3 Million by 2030, with a CAGR of 9.7% from 2023 to 2031".

Excipients are carrier substances that are useful in the formulation of biopharmaceuticals. They provide effective ingredient binding, improve drug stability in the dosage form, and alter API solubility. Minerals, sugar, corn, wheat, and other similar components make inert, repeatable excipients. They can increase production, lower operational expenses, and raise the caliber of the final output. Biologics' escalating popularity over time has caused a paradigm change in the healthcare sector. The US FDA has steadily increased the number of biopharmaceuticals it approves yearly, including gene treatments, vaccines, recombinant proteins, and monoclonal antibodies, only in the past ten years. Currently, over 8,000 biological pharmaceutical compounds are being tested in clinical settings across the globe.

Free PDF Report Brochure @ https://www.insightaceanalytic.com/request-sample/1197

The expanding uses of excipients increased market player efforts to create excipients for novel, high-quality drugs, increasing emphasis on developing novel drugs, rising rates of chronic diseases, expanding use of lipid and sucrose-based excipients, and technological advancements in pharmaceutical manufacturing. Advancing R&D activities in the pharmaceutical industry are the primary factors driving the biopharmaceutical excipient manufacturing market. The burden of producing drugs for biopharmaceutical companies to treat the affected individuals has increased due to the rising COVID instances. As a result, companies are placing a greater emphasis on quick drug development. Excipients work well and efficiently to improve the production of biopharmaceuticals. There is a growing need for biopharmaceutical excipients to produce novel and stabilized medications, which will lead to considerable development prospects throughout the projection period. However, throughout the projected period, market expansion may be hampered by the difficulties involved in medication manufacturing and the large capital expenditure needed.

Regional Outlook:

North America is anticipated to be the major contributor to the Biopharmaceutical Excipient Manufacturing market ascribed to various elements, including important players, an increase in drug research, and a sizable population base. Collaborations between businesses in this area are being used to produce biopharmaceutical excipients. In addition, the Asia Pacific regional market is expected to register significant growth since the prevalence of chronic diseases is rising, healthcare spending is increasing, and drug demand is rising. China and India are the two developing nations in this sector.

Recent Collaborations and Agreements in the Market:

In May 2023, Corden pharma has announced its initiation of oligonucleotide API production. Through two phases of organic capex, the strategic expansion will provide innovative biotech and pharma clients with a fully-integrated API to Drug Product service offering structured on a new Oligonucleotides Platform.

In Nov 2022, DFE Pharma and Azelis have announced an EMEA distribution agreement. This new partnership enabled Azelis to distribute exclusively the following DFE Pharma excipients: Nutracel, Pharmacel, and Pharmacel sMCC90, which are high-quality MCCs (microcrystalline cellulose) and co-processed MCCs (microcrystalline cellulose) used as fillers and binders in oral dosage forms. The agreement also covered the powerful disintegrant Primellose (sodium croscarmellose), which is used in oral dosage forms.

In Dec 2022, BASF Pharma Solutions, BASF's pharmaceutical division, stated that the US Food and Drug Administration (USFDA) had approved its pharmaceutical grade excipient, Soluplus, for the FDA's pilot programme for evaluating excipient innovation and modernization.

In April 2020, DFE Pharma recently introduced a new line of biopharmaceutical excipients to stabilize biologics. The highest purity excipients that can be utilized in the formulation are included in BioHale, a new spectrum of excipients. It is currently being developed and will be sold online. It contains BioHale Sucrose and BioHale Trehalose.

Major market players operating in the Biopharmaceutical Excipient Manufacturing market include

ABITEC Corporation

Aceto

Angus Chemical

Apothecon

Ashland Global

Associated British Foods plc

Avantor

BASF SE

BioSpectra

BOC Sciences

C.G. Group

Clariant

Colorcon

Croda International Plc

DFE Pharma

DOW

Eastman Chemical

Evonik Industries AG

IMCD N.V.

Innophos

Invitria

J. RETTENMAIER & SÖHNE GmbH + Co KG

Kirsch Pharma

Meggle Pharma

Merck KGaA

Novo Nordisk

Pfanstiehl, Inc.

Pharmonix

Roquette Freres

Shin-Etsu Chemical

Sigachi Industries Limited

Signet Excipients Pvt. Ltd (IMCD)

Spectrum Chemical Manufacturing Corp.

SPI Pharma

Stepan Company

Tereos

The Lubrizol

Wacker Chemie

Biopharmaceutical Excipient Manufacturing Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 1259.8 Billion

Revenue Forecast In 2030

USD 2624.3 Million

Growth Rate CAGR

CAGR of 9.7 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Billion and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product Type, By Type of Biologics, By Scale Of Operation

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Enquiry Before Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1197

Market Segments

Global Biopharmaceutical Excipient Manufacturing Market, by Product Type, 2023-2030 (Value US$ Mn)

Solubilizers & Surfactants/Emulsifiers

Triglycerides

Esters

Others (Sodium Cocoyl Glutamate, Glyceryl Caprylate; Citric Acid; Polyglyceryl-6 Oleate; Sodium Surfactin)

Polyols

Mannitol

Sorbitol

Others (Lactitol, Isomalt, xylitol)

Carbohydrates

Sucrose

Dextrose

Starch

Others (Lactose, Cellolose, Fructose)

Specialty Excipients

Global Biopharmaceutical Excipient Manufacturing Market, by Type of Biologics, 2023-2030 (Value US$ Mn)

Antibodies

Vaccines

Cell Therapies

Other Biologics

Global Biopharmaceutical Excipient Manufacturing Market, by Scale of Operation, 2023-2030 (Value US$ Mn)

Commercial

Research

Global Biopharmaceutical Excipient Manufacturing Market, by Region, 2023-2030 (Value US$ Mn)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

North America Biopharmaceutical Excipient Manufacturing Market, by Country, 2023-2030 (Value US$ Mn)

U.S.

Canada

Europe Biopharmaceutical Excipient Manufacturing Market, by Country, 2023-2030 (Value US$ Mn)

Germany

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific Biopharmaceutical Excipient Manufacturing Market, by Country, 2023-2030 (Value US$ Mn)

India

China

Japan

South Korea

Australia & New Zealand

Latin America Biopharmaceutical Excipient Manufacturing Market, by Country, 2023-2030 (Value US$ Mn)

Brazil

Mexico

Rest of Latin America

Middle East & Africa Biopharmaceutical Excipient Manufacturing Market, by Country, 2023-2030 (Value US$ Mn)

GCC Countries

South Africa

Rest of Middle East & Africa

Get Customized Report @ https://www.insightaceanalytic.com/customisation/1197

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/